ClinicalTrials.gg
CompletedNCT01453023Updated Jan 11, 2017Results posted

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

A Phase 2 interventional study of Fluticasone Furoate and Fluticasone Furoate/Vilanterol in Asthma, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-01-11.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
5 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
33rd of 40
26 · median 102
Started
2011
with 3 others
Phase 2
12 of 40
none open now
Registered
21st of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 33rd largest by enrollment, is one of 4 that started in 2011, is one of 12 in phase 2, and was the 21st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

This study will investigate the safety and tolerability, pharmacokinetics, and pharmacodynamics of fluticasone furoate/vilanterol (FF/VI) 100/25mcg administered using the novel dry powder inhaler in children aged 5 to 11 years with persistent asthma.

Read the detailed description

This study will investigate the safety and tolerability, pharmacokinetics, and pharmacodynamics of fluticasone furoate/vilanterol (FF/VI) 100/25mcg administered using the novel dry powder inhaler in children aged 5 to 11 years with persistent asthma. Fluticasone furoate (FF, GW685698) is a novel once daily inhaled corticosteroid (ICS) and vilanterol (VI, GW642444) is an inhaled once daily long-acting beta2 agonist (LABA). FF/VI is a novel ICS/LABA combination with once-daily dosing being developed for the treatment of asthma in adults, adolescents, and children of 5 years and above.

This study will be a randomized, double-blind, repeat dose, two period crossover study, with FF as the control. During each of two treatment periods subjects will receive either FF/VI 100/25 micrograms (mcg) or FF 100 mcg daily on 14 consecutive mornings via the novel dry powder inhaler. Approximately 26 subjects will be recruited into this study, with a target of 20 completed subjects. Safety, tolerability, pharmacokinetics and glucose , potassium and cortisol levels will be investigated.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • pediatric ages 5 to 11 years
04

Who can participate

Ages eligible
5 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy as determined by a study physician, based medical history, physical examination, laboratory testing, and (ECG); with no significant medical condition apart from asthma, eczema, or rhinitis. A subject with a clinical abnormality or laboratory parameters outside the reference range for this study may be included if the Investigator and GSK Medical Monitor agree the finding is unlikely to introduce additional risk factors or interfere with the study procedures.
  • Male and pre-menarchial female subjects aged 5 to less than 12 years on the last planned treatment day are eligible for this study. Pre-menarchial females are defined as any female who has not begun menses and is considered Tanner Stage 2 or less.
  • Diagnosis of asthma at least 6 months prior to screening.
  • Stable asthma therapy (fluticasone propionate, total daily dose less than or equal to 400 microgram or equivalent) and short acting beta-agonist (SABA) inhaler for at least 4 weeks prior to screening.
  • Subjects must be controlled on their existing asthma treatment at screening, which will be continued during the run-in, washout and run-out periods (but not during active treatment periods). Control is defined as a Childhood Asthma Control Test score of >19 and (Peak Expiratory Flow) PEF more than 75 percent predicted.
  • Subjects must demonstrate an ability to accept and effectively use a demonstration inhaler from the demonstration kits provided.
  • Subjects must weigh at least 20 kilograms.
  • The subject and parent/guardian are able to understand and comply with protocol requirements, instructions, and protocol stated restrictions. The parent or guardian must have the ability to read, write, and record diary information collected throughout the study. The parent or guardian must have the ability to manage study drug administration and PEF assessments.
  • At least one parent/guardian has signed and dated the written prior to admission to the study. This will be accompanied by informed assent from the subject for children aged 7 to 11 years.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a history of life-threatening asthma, an asthma exacerbation requiring systemic or Emergency Room attendance (within 3 months) or requiring hospitalization (within 6 months) prior to screening.
  • Subjects with any medical condition or circumstance making the volunteer unsuitable for participation in the study.
  • Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear, not resolved within 4 weeks of screening leading to a change in asthma management; or, in the opinion of the investigator, is likely to affect the subject's asthma status or ability to participate in the study.
  • Clinical visual evidence of oral candidiasis at screening.
  • Subjects currently receiving (or have received within 4 weeks of screening) asthma therapies including theophyllines, long-acting inhaled beta-agonists, oral beta-agonists, or who have changed their asthma medication within 4 weeks of screening.
  • Significant abnormality of rate, interval, conduction or rhythm in the 12-lead (electrocardiogram), determined by the investigator in conjunction with the age and gender of the child and the assessment provided by the remote analysis service.
  • (QT interval corrected for heart rate using Fridericia's formula) more than 450 milliseconds or an ECG not suitable for QT measurement (e.g. poorly defined termination of the T wave).
  • Aspartarte aminotransferase, , alkaline phosphatase and more than 1.5 times (ULN) (isolated bilirubin more than 1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35 percent).
  • A known or suspected sensitivity to any constituents of the novel dry powder inhaler (i.e. lactose or magnesium stearate) (e.g. history of severe milk protein allergy)
  • Any adverse reaction including immediate or delayed to any beta-2-agonist, sympathomimetic drug, or any intranasal, inhaled or systemic corticosteroid therapy.
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • Consumption of red wine, seville oranges, grapefruit or grapefruit juice, and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
  • The subject has participated in a clinical trial and has received an product within 30 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Where participation in the study would result in donation of blood or blood products in excess of the lesser of 50 millilitres (mL) or 3mL per kilogram within a 56 day period.
  • Parent/guardian has a history of psychiatric disease, intellectual deficiency, substance abuse, or other condition (e.g. inability to read, comprehend and write) which will limit the validity of consent to participate in this study.
  • Unwillingness or inability of the subject or parent/guardian to follow the procedures outlined in the protocol.
  • Subject who is mentally or legally incapacitated.
  • Children who are wards of the state or government.
  • A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
26 participants (actual)

Study arms

  • Active comparator
    Fluticasone Furoate

    One of two study treatments subjects will receive. Given to allow comparison of FF exposure in combination versus as mono therapy.

    Drug: Fluticasone Furoate

  • Experimental
    Fluticasone Furoate/Vilanterol

    One of two study treatments subjects will receive. FF/VI combined is being tested and compared to fluticasone furoate.

    Drug: Fluticasone Furoate/Vilanterol

Interventions

  • 100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.

    Also known as: FF

  • DrugFluticasone Furoate/Vilanterol

    Drug pages: Fluticasone furoate · Vilanterol

    100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.

    Also known as: FF/VI

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.

    Time frame: From the start of study medication until Week 11 (Visit 9)/Early Withdrawal

  2. Basophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil, Platelet, and White Blood Cell Count Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelets, and white blood cell (WBC) count at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  3. Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of hemoglobin and MCHC at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  4. Reticulocyte and Red Blood Cell (RBC) Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of reticulocytes and RBCs at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  5. Hematocrit Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of hematocrit at Day 14 of the respective treatment period. Hematocrit is a measure of the percentage of the volume of the whole blood that is composed of red blood cells, as determined by separation of red blood cells from the plasma (usually by centrifugation).

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  6. Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of MCV at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  7. Mean Corpuscle Hemoglobin (MCH) Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of MCH at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  8. Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of ALT, ALP, AST, and GGT at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  9. Albumin and Total Protein Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of albumin and total protein at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  10. Calcium, Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of calcium, chloride, carbon dioxide content/bicarbonate (CO2/BI), glucose, potassium, sodium, and urea/BUN at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  11. Total Bilirubin, Direct Bilirubin, Creatinine, and Uric Acid Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of total bilirubin, direct bilirubin, creatinine, and uric acid at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  12. Peak Expiratory Flow on Day 1 and Day 14 of the Respective Treatment Period

    Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF is calculated as the maximum of three readings taken at each timepoint for each participant. Baseline is defined as the maximum pre-dose measurement at Day 1 for each period.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)

  13. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1 and Day 14 of the Respective Treatment Period

    SBP and DBP were measured at Day 1 and Day 14 of the respective treatment period. Baseline is defined as the pre-dose measurement at Day 1. Change from Baseline was calculated as the Day 14 value minus the Baseline value.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)

  14. Change From Baseline in Heart Rate at Day1 and Day 14 of the Respective Treatment Period

    Heart rate (HR) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. Baseline is defined as the pre-dose measurement at Day 1. Change from Baseline was calculated as the Day 14 value minus the Baseline value. Treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)

  15. Maximum QTcF at Day 1 and Day 14 of the Respective Treatment Period

    QTcF is the QT domain corrected for heart rate by Fridericia's formula. Treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)

Secondary outcomes

  1. AUC(0-t) and AUC(0-4) of FF on Day 14 of the Respective Treatment Period

    Area under the concentration-time (AUC) curve from time zero (pre-dose) to the last time AUC(0-t) and from time zero to 4 hours AUC(0-4) of quantifiable concentration of FF on Day 14 of the respective treatment period was measured. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the PK Population.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  2. Cmax of FF on Day 14 of the Respective Treatment Period

    Cmax is defined as the maximum observed concentration of FF on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  3. Tmax and Tlast of FF on Day 14 of the Respective Treatment Period

    tmax is defined as the time to reach the observed maximum concentration, and tlast is defined as the time of the last observed quantifiable concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  4. AUC(0-t) and AUC(0-4) of VI on Day 14 of the Respective Treatment Period

    Area under the concentration-time (AUC) curve from time zero (pre-dose) to the last time AUC(0-t) and from time zero to 4 hours AUC(0-4) of quantifiable concentration of VI on Day 14 of the respective treatment period was measured. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the VI PK Population.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  5. Cmax of VI on Day 14 of the Respective Treatment Period

    Cmax is defined as the maximum observed concentration of VI on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  6. Tmax and Tlast of VI on Day 1 of the Respective Treatment Period

    tmax is defined as the time to reach the observed maximum VI concentration, and tlast is defined as the time of the last observed quantifiable VI concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  7. Blood Glucose and Potassium Values on Day 14 of the Respective Treatment Period

    Blood glucose and potassium values were measured on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose. Weighted means were derived using the linear trapezoidal rule. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative time were used for these observations. Treatment and period were fitted as fixed effects and participant was fitted as a random effect.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  8. Serum Cortisol (SC) Weighted Mean (0-12 Hours) on Day 14 of the Respective Treatment Period

    SC weighted mean was determined for each participant over the time period of 0-12 hours on Day 14 of the respective treatment period. SC weighted mean was derived by dividing the area under the concentration-time curve (AUC; defined as thearea under the concentration-time curve from time zero up to 24 hours) by the sample collection time interval. The sample collection time interval is defined as the difference between the time of the last cortisol sample and the time of the first cortisol sample. Samples were collected at the following time points: 0 (first blood draw/pre-dose); 2, 4, 8, and 12 hours (relative to the "0" time point). Weighted means were derived using the linear trapezoidal rule. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative time were used for these observations. Treatment and period were fitted as fixed effects and participant was fitted as a random effect.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  9. Average Oropharyngeal Cross-sectional Area on Day 1 and Day 14 of the Respective Treatment Period

    During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for the study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Pharyngometry data were recorded for each day (Day 1 and Day 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day X)

  10. Distance of Assessment on Day 1 and Day 14 of the Respective Treatment Period

    During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Distance of assessment is defined as the distance (length measured in centimeters \[cm\]) estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)

  11. Oropharyngeal Volume on Day 1 and Day 14 of the Respective Treatment Period

    During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Oropharyngeal volume is defined as the volume (cm\^3) of the mouth and throat estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)

  12. Average Flow Rate and Peak Inspiratory Flow Rate (PIFR) on Day 1 and Day 14 of the Respective Treatment Period

    During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Average flow rate is defined as the average inspiratory flow rate (Liters \[L\]/min) across the inhalation profile when inhaling across the resistance of the inhaler. PIFR is defined as the Peak Inspiratory Flow Rate (L/min) of the inhalation profile when inhaling across the resistance of the inhaler.The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the average flow rate and PIFR were determined.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)

  13. Inhalation Time on Days 1 and 14 of of the Respective Treatment Period

    During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhalation time is defined as the duration of the inhalation(s) when inhaling across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalation time was determined.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)

  14. Inhaled Volume on Days 1 and 14 of the Respective Treatment Period

    During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhaled volume is defined as the volume of air (Liters) inhaled during the inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalaled volume was determined.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)

  15. Peak Pressure Drop on Days 1 and 14 of the Respective Treatment Period

    During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Peak pressure drop is defined as the maximum pressure drop (kilopascal \[kPa\]) achieved during inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was calculated for each day (Days 1 and 14 of the respective treatment period), and used for subsequent modeling and prediction of dose emission attributes.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)

  16. Total Emitted Dose (TED) on Day 14 of the Respective Treatment Period

    The total emitted dose (TED) is defined as the mass (micrograms) of the nominal dose that passes beyond the throat. The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted total emitted dose.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

  17. Ex-throat Dose (ETD) and ETD <2 Microns on Day 14 of the Respective Treatment Period

    The ex-throat dose (ETD) and the "nominal ETD" is the mass (micrograms) of active investigational material that passes beyond the throat, nominal being the mean. The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted ETD and ETD \<2 microns.

    Time frame: Day 14 of the respective treatment period (up to Study Day 63)

07

Results

Posted Aug 9, 2013

Participant flow

Participants were enrolled into one of two cohorts based upon age; the younger cohort was enrolled after a review of the safety/pharmacokinetic data of at least six participants from the older cohort. Each participant was assigned to treatment randomly; assignment was not to be influenced by whether participants were in Cohort 1 or Cohort 2.

Treatment Period (TP) 1
Participant flow — Treatment Period (TP) 1
MilestoneFF 100 µg/VI 25 µg in TP 1 and FF 100 µg in TP 2FF 100 µg in TP 1 and FF 100 µg/VI 25 µg in TP 2
Started1313
Completed1212
Not completed11
Withdrew: Protocol violation10
Withdrew: Met protocol-defined stopping criteria01
Washout Period
Participant flow — Washout Period
MilestoneFF 100 µg/VI 25 µg in TP 1 and FF 100 µg in TP 2FF 100 µg in TP 1 and FF 100 µg/VI 25 µg in TP 2
Started1212
Completed1212
Not completed00
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneFF 100 µg/VI 25 µg in TP 1 and FF 100 µg in TP 2FF 100 µg in TP 1 and FF 100 µg/VI 25 µg in TP 2
Started1212
Completed1211
Not completed01
Withdrew: Protocol violation01

Outcome measures

PrimaryNumber of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.

Time frame:
From the start of study medication until Week 11 (Visit 9)/Early Withdrawal
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period
ParticipantsFF 100 µg/VI 25 µgFF 100 µg
Any AE41
Any SAE00
PrimaryBasophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil, Platelet, and White Blood Cell Count Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelets, and white blood cell (WBC) count at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · 10^9 cells per liter (GI/L)
Basophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil, Platelet, and White Blood Cell Count Values at Day 14 of the Respective Treatment Period
10^9 cells per liter (GI/L)FF 100 µg/VI 25 µgFF 100 µg
Basophils, n=21, 230.025 ± 0.01750.025 ± 0.0153
Eosinophils, n=21, 230.296 ± 0.33950.293 ± 0.3957
Lymphocytes, n=21, 232.062 ± 0.84622.339 ± 0.7391
Monocytes, n=21, 230.244 ± 0.11880.222 ± 0.1375
Total neutrophils, n=21, 233.805 ± 2.40903.106 ± 1.3526
Platelets, n=21, 23270.5 ± 92.27299.0 ± 73.66
WBC count, n=21, 236.43 ± 2.8895.98 ± 1.897
PrimaryHemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of hemoglobin and MCHC at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · Grams per liter (g/L)
Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Values at Day 14 of the Respective Treatment Period
Grams per liter (g/L)FF 100 µg/VI 25 µgFF 100 µg
Hemoglobin, n=21, 23125.9 ± 13.49128.0 ± 6.52
MCHC, n=21, 23330.3 ± 5.83330.8 ± 7.88
PrimaryReticulocyte and Red Blood Cell (RBC) Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of reticulocytes and RBCs at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · 10^12 cells per liter (TI/L)
Reticulocyte and Red Blood Cell (RBC) Values at Day 14 of the Respective Treatment Period
10^12 cells per liter (TI/L)FF 100 µg/VI 25 µgFF 100 µg
Reticulocytes, n=21, 230.07220 ± 0.0374730.07323 ± 0.032203
RBCs, n=21, 234.33 ± 0.4674.38 ± 0.199
PrimaryHematocrit Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of hematocrit at Day 14 of the respective treatment period. Hematocrit is a measure of the percentage of the volume of the whole blood that is composed of red blood cells, as determined by separation of red blood cells from the plasma (usually by centrifugation).

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · proportion of 1
Hematocrit Values at Day 14 of the Respective Treatment Period
proportion of 1FF 100 µg/VI 25 µgFF 100 µg
Hematocrit Values at Day 14 of the Respective Treatment Period0.3816 ± 0.041990.3866 ± 0.02160
PrimaryMean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of MCV at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · 10^15 femtoliters (fL) per cell
Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period
10^15 femtoliters (fL) per cellFF 100 µg/VI 25 µgFF 100 µg
Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period87.9 ± 2.6188.6 ± 3.37
PrimaryMean Corpuscle Hemoglobin (MCH) Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of MCH at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · 10^12 picograms (pg) per cell
Mean Corpuscle Hemoglobin (MCH) Values at Day 14 of the Respective Treatment Period
10^12 picograms (pg) per cellFF 100 µg/VI 25 µgFF 100 µg
Mean Corpuscle Hemoglobin (MCH) Values at Day 14 of the Respective Treatment Period29.03 ± 0.94129.25 ± 1.116
PrimaryAlanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of ALT, ALP, AST, and GGT at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · International units per liter (IU/L)
Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) Values at Day 14 of the Respective Treatment Period
International units per liter (IU/L)FF 100 µg/VI 25 µgFF 100 µg
ALT, n=22, 2416.9 ± 14.6317.7 ± 14.88
ALP, n=22, 24278.4 ± 110.01272.6 ± 119.48
AST, n=22, 2428.2 ± 8.3829.0 ± 7.51
GGT, n=22, 2414.6 ± 7.7416.1 ± 10.36
PrimaryAlbumin and Total Protein Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of albumin and total protein at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · Grams per liter
Albumin and Total Protein Values at Day 14 of the Respective Treatment Period
Grams per literFF 100 µg/VI 25 µgFF 100 µg
Albumin, n=22, 2445.5 ± 1.9745.6 ± 2.20
Total protein, n=22, 2470.4 ± 2.9970.4 ± 3.12
PrimaryCalcium, Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of calcium, chloride, carbon dioxide content/bicarbonate (CO2/BI), glucose, potassium, sodium, and urea/BUN at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · Millimoles per liter (mmol/L)
Calcium, Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 14 of the Respective Treatment Period
Millimoles per liter (mmol/L)FF 100 µg/VI 25 µgFF 100 µg
Calcium, n=22, 242.416 ± 0.05912.415 ± 0.0749
Chloride, n=22, 24103.3 ± 1.75103.8 ± 1.79
CO2 content/bicarbonate, n=22, 2419.0 ± 1.8519.1 ± 2.05
Glucose, n=22, 244.50 ± 0.6894.53 ± 0.523
Potassium, n=22, 244.24 ± 0.1844.27 ± 0.265
Sodium, n=22, 24138.6 ± 1.84139.0 ± 1.85
Urea/BUN, n=22, 244.52 ± 1.0064.52 ± 1.108
PrimaryTotal Bilirubin, Direct Bilirubin, Creatinine, and Uric Acid Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of total bilirubin, direct bilirubin, creatinine, and uric acid at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · Micromoles per liter (µmol/L)
Total Bilirubin, Direct Bilirubin, Creatinine, and Uric Acid Values at Day 14 of the Respective Treatment Period
Micromoles per liter (µmol/L)FF 100 µg/VI 25 µgFF 100 µg
Total bilirubin, n=22, 246.1 ± 1.445.9 ± 1.72
Direct bilirubin, n=22, 241.7 ± 0.701.9 ± 0.41
Creatinine, n=22, 2436.00 ± 7.61737.09 ± 6.225
Uric acid, n=22, 24231.8 ± 64.85233.8 ± 54.04
PrimaryPeak Expiratory Flow on Day 1 and Day 14 of the Respective Treatment Period

Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF is calculated as the maximum of three readings taken at each timepoint for each participant. Baseline is defined as the maximum pre-dose measurement at Day 1 for each period.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · liters/minute
Peak Expiratory Flow on Day 1 and Day 14 of the Respective Treatment Period
liters/minuteFF 100 µg/VI 25 µgFF 100 µg
Day 1, Baseline, n=25, 25219.0 ± 53.27223.6 ± 56.91
Day 1, 10 minutes post-dose, n=25, 25218.8 ± 53.02223.0 ± 55.15
Day 1, 20 minutes post-dose, n=25, 25222.4 ± 53.50228.2 ± 56.73
Day 1, 1 hour post-dose, n=25, 25223.2 ± 54.23227.2 ± 54.07
Day 1, 2 hours post-dose, n=25, 25227.0 ± 55.94228.6 ± 54.17
Day 14, Pre-dose, n=23, 24224.8 ± 52.86215.0 ± 50.71
Day 14, 20 minutes post-dose, n=23, 24227.2 ± 52.18218.1 ± 52.12
Day 14, 2 hours post-dose, n=23, 24235.7 ± 53.16225.8 ± 48.78
Day 14, 12 hours post-dose, n=23, 24238.9 ± 55.84230.4 ± 52.54
PrimaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1 and Day 14 of the Respective Treatment Period

SBP and DBP were measured at Day 1 and Day 14 of the respective treatment period. Baseline is defined as the pre-dose measurement at Day 1. Change from Baseline was calculated as the Day 14 value minus the Baseline value.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1 and Day 14 of the Respective Treatment Period
Millimeters of mercury (mmHg)FF 100 µg/VI 25 µgFF 100 µg
Day 1 SBP, Baseline, n=25, 2597.2 ± 5.4199.9 ± 6.71
Day 1 SBP, 20 minutes, n=25, 25-0.1 ± 2.98-0.1 ± 4.66
Day 1 SBP, 1 hour, n=25, 250.5 ± 2.870.4 ± 3.70
Day 1 SBP, 2 hours, n=25, 250.9 ± 3.051.3 ± 2.95
Day 14 SBP, Pre-dose, n=23, 241.3 ± 4.32-1.2 ± 6.92
Day 14 SBP, 20 minutes, n=23, 241.3 ± 4.61-1.2 ± 6.03
Day 14 SBP, 1 hour, n=23, 241.0 ± 4.42-0.8 ± 6.36
Day 14 SBP, 2 hours, n=23, 241.7 ± 4.17-0.8 ± 6.34
Day 14 SBP, 4 hours, n=23, 242.1 ± 4.220.1 ± 6.47
Day 14 SBP, 8 hours, n=23, 242.0 ± 4.33-0.4 ± 7.17
Day 1 DBP, Baseline, n=25, 2562.3 ± 3.5463.6 ± 3.86
Day 1 DBP, 20 minutes, n=25, 250.3 ± 2.81-0.3 ± 3.76
Day 1 DBP, 1 hour, n=25, 251.0 ± 3.170.8 ± 3.11
Day 1 DBP, 2 hours, n=25, 250.9 ± 3.421.0 ± 3.38
Day 14 DBP, Pre-dose, n=23, 240.6 ± 3.540.2 ± 3.29
Day 14 DBP, 20 minutes, n=23, 240.1 ± 3.690.1 ± 2.62
Day 14 DBP, 1 hour, n=23, 240.4 ± 4.180.0 ± 2.30
Day 14 DBP, 2 hours, n=23, 241.3 ± 3.750.4 ± 3.19
Day 14 DBP, 4 hours, n=23, 241.1 ± 4.171.1 ± 3.35
Day 14 DBP, 8 hours, n=23, 241.4 ± 3.27-0.2 ± 3.02
PrimaryChange From Baseline in Heart Rate at Day1 and Day 14 of the Respective Treatment Period

Heart rate (HR) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. Baseline is defined as the pre-dose measurement at Day 1. Change from Baseline was calculated as the Day 14 value minus the Baseline value. Treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Least squares mean · Beats per minute
Change From Baseline in Heart Rate at Day1 and Day 14 of the Respective Treatment Period
Beats per minuteFF 100 µg/VI 25 µgFF 100 µg
Day 1, n=25, 2584.4 ± 1.6388.6 ± 1.63
Day 14, n=23, 2489.4 ± 1.7185.7 ± 1.67
Statistical analysis
  • FF 100 µg/VI 25 µg vs FF 100 µg · Mean difference (final values): -4.2 · 95% CI -8.8 to 0.4Day 1 HR. The estimated value represents the treatment difference: FF/VI 100/25 µg minus FF 100 µg.
  • FF 100 µg/VI 25 µg vs FF 100 µg · Mean difference (final values): 3.7 · 95% CI -1.1 to 8.5Day 14 HR. The estimated value represents the treatment difference: FF/VI 100/25 µg minus FF 100 µg.
PrimaryMaximum QTcF at Day 1 and Day 14 of the Respective Treatment Period

QTcF is the QT domain corrected for heart rate by Fridericia's formula. Treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Least squares mean · milliseconds
Maximum QTcF at Day 1 and Day 14 of the Respective Treatment Period
millisecondsFF 100 µg/VI 25 µgFF 100 µg
Day 1 QTcF, n=25, 25403.3 ± 1.98402.2 ± 1.98
Day 14 QTcF, n=23, 24404.0 ± 2.06404.2 ± 2.02
Statistical analysis
  • FF 100 µg/VI 25 µg vs FF 100 µg · Mean difference (final values): 1.2 · 95% CI -4.4 to 6.7Day 1 QTcF. The estimated value represents the treatment difference: FF/VI 100/25 µg minus FF 100 µg.
  • FF 100 µg/VI 25 µg vs FF 100 µg · Mean difference (final values): -0.3 · 95% CI -6.0 to 5.5Day 14 QTcF. The estimated value represents the treatment difference: FF/VI 100/25 µg minus FF 100 µg.
SecondaryAUC(0-t) and AUC(0-4) of FF on Day 14 of the Respective Treatment Period

Area under the concentration-time (AUC) curve from time zero (pre-dose) to the last time AUC(0-t) and from time zero to 4 hours AUC(0-4) of quantifiable concentration of FF on Day 14 of the respective treatment period was measured. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the PK Population.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Geometric mean · picograms*hour per milliliter (pg*hr/mL)
AUC(0-t) and AUC(0-4) of FF on Day 14 of the Respective Treatment Period
picograms*hour per milliliter (pg*hr/mL)FF 100 µg/VI 25 µgFF 100 µg
AUC(0-t), n=23, 2438.895 (21.630 to 69.941)32.880 (18.268 to 59.179)
AUC(0-4), n=17, 1586.14 (70.03 to 105.96)83.83 (71.49 to 98.30)
SecondaryCmax of FF on Day 14 of the Respective Treatment Period

Cmax is defined as the maximum observed concentration of FF on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Geometric mean · picograms per milliliter (pg/mL)
Cmax of FF on Day 14 of the Respective Treatment Period
picograms per milliliter (pg/mL)FF 100 µg/VI 25 µgFF 100 µg
Cmax of FF on Day 14 of the Respective Treatment Period20.73 (15.16 to 28.36)21.16 (14.91 to 30.02)
SecondaryTmax and Tlast of FF on Day 14 of the Respective Treatment Period

tmax is defined as the time to reach the observed maximum concentration, and tlast is defined as the time of the last observed quantifiable concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Median · hours
Tmax and Tlast of FF on Day 14 of the Respective Treatment Period
hoursFF 100 µg/VI 25 µgFF 100 µg
tmax, n=20, 190.965 (0.00 to 2.07)0.500 (0.00 to 3.95)
tlast, n=20, 194.030 (0.52 to 4.13)4.020 (1.03 to 4.05)
SecondaryAUC(0-t) and AUC(0-4) of VI on Day 14 of the Respective Treatment Period

Area under the concentration-time (AUC) curve from time zero (pre-dose) to the last time AUC(0-t) and from time zero to 4 hours AUC(0-4) of quantifiable concentration of VI on Day 14 of the respective treatment period was measured. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the VI PK Population.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Geometric mean · picograms*hour per milliliter (pg*hr/mL)
AUC(0-t) and AUC(0-4) of VI on Day 14 of the Respective Treatment Period
picograms*hour per milliliter (pg*hr/mL)FF 100 µg/VI 25 µgFF 100 µg
AUC(0-t), n=2344.297 (26.996 to 72.688)—
AUC(0-4), n=11119.19 (102.41 to 138.73)—
SecondaryCmax of VI on Day 14 of the Respective Treatment Period

Cmax is defined as the maximum observed concentration of VI on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Geometric mean · picograms per milliliter (pg/mL)
Cmax of VI on Day 14 of the Respective Treatment Period
picograms per milliliter (pg/mL)FF 100 µg/VI 25 µgFF 100 µg
Cmax of VI on Day 14 of the Respective Treatment Period44.21 (27.65 to 70.70)—
SecondaryTmax and Tlast of VI on Day 1 of the Respective Treatment Period

tmax is defined as the time to reach the observed maximum VI concentration, and tlast is defined as the time of the last observed quantifiable VI concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Median · hours
Tmax and Tlast of VI on Day 1 of the Respective Treatment Period
hoursFF 100 µg/VI 25 µgFF 100 µg
tmax, n=210.170 (0.00 to 2.08)—
tlast, n=213.870 (0.50 to 4.13)—
SecondaryBlood Glucose and Potassium Values on Day 14 of the Respective Treatment Period

Blood glucose and potassium values were measured on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose. Weighted means were derived using the linear trapezoidal rule. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative time were used for these observations. Treatment and period were fitted as fixed effects and participant was fitted as a random effect.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Least squares mean · Millimoles per liter (mmol/L)
Blood Glucose and Potassium Values on Day 14 of the Respective Treatment Period
Millimoles per liter (mmol/L)FF 100 µg/VI 25 µgFF 100 µg
Glucose, n=22, 245.578 ± 0.14955.074 ± 0.1443
Potassium, n=21, 234.059 ± 0.04484.148 ± 0.0426
SecondarySerum Cortisol (SC) Weighted Mean (0-12 Hours) on Day 14 of the Respective Treatment Period

SC weighted mean was determined for each participant over the time period of 0-12 hours on Day 14 of the respective treatment period. SC weighted mean was derived by dividing the area under the concentration-time curve (AUC; defined as thearea under the concentration-time curve from time zero up to 24 hours) by the sample collection time interval. The sample collection time interval is defined as the difference between the time of the last cortisol sample and the time of the first cortisol sample. Samples were collected at the following time points: 0 (first blood draw/pre-dose); 2, 4, 8, and 12 hours (relative to the "0" time point). Weighted means were derived using the linear trapezoidal rule. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative time were used for these observations. Treatment and period were fitted as fixed effects and participant was fitted as a random effect.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Geometric mean · nanomoles per Liter
Serum Cortisol (SC) Weighted Mean (0-12 Hours) on Day 14 of the Respective Treatment Period
nanomoles per LiterFF 100 µg/VI 25 µgFF 100 µg
Serum Cortisol (SC) Weighted Mean (0-12 Hours) on Day 14 of the Respective Treatment Period193.77 ± 0.069192.50 ± 0.069
SecondaryAverage Oropharyngeal Cross-sectional Area on Day 1 and Day 14 of the Respective Treatment Period

During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for the study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Pharyngometry data were recorded for each day (Day 1 and Day 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day X)
Reported as:
Mean · centimeters squared (cm^2)
Average Oropharyngeal Cross-sectional Area on Day 1 and Day 14 of the Respective Treatment Period
centimeters squared (cm^2)FF 100 µg/VI 25 µgFF 100 µg
Day 1, n=23, 234.13 ± 2.0103.85 ± 2.043
Day 14, n=23, 233.76 ± 2.1953.70 ± 2.279
SecondaryDistance of Assessment on Day 1 and Day 14 of the Respective Treatment Period

During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Distance of assessment is defined as the distance (length measured in centimeters \[cm\]) estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · centimeters (cm)
Distance of Assessment on Day 1 and Day 14 of the Respective Treatment Period
centimeters (cm)FF 100 µg/VI 25 µgFF 100 µg
Day 1, n=23, 2319.20 ± 1.09719.24 ± 0.959
Day 14, n=23, 2319.26 ± 0.71719.10 ± 1.003
SecondaryOropharyngeal Volume on Day 1 and Day 14 of the Respective Treatment Period

During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Oropharyngeal volume is defined as the volume (cm\^3) of the mouth and throat estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · Liters per minute (L/min)
Oropharyngeal Volume on Day 1 and Day 14 of the Respective Treatment Period
Liters per minute (L/min)FF 100 µg/VI 25 µgFF 100 µg
Day 1, n=23, 2379.49 ± 43.39875.54 ± 44.195
Day 14, n=23, 2372.35 ± 42.43771.47 ± 45.841
SecondaryAverage Flow Rate and Peak Inspiratory Flow Rate (PIFR) on Day 1 and Day 14 of the Respective Treatment Period

During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Average flow rate is defined as the average inspiratory flow rate (Liters \[L\]/min) across the inhalation profile when inhaling across the resistance of the inhaler. PIFR is defined as the Peak Inspiratory Flow Rate (L/min) of the inhalation profile when inhaling across the resistance of the inhaler.The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the average flow rate and PIFR were determined.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · Liters per minute (L/min)
Average Flow Rate and Peak Inspiratory Flow Rate (PIFR) on Day 1 and Day 14 of the Respective Treatment Period
Liters per minute (L/min)FF 100 µg/VI 25 µgFF 100 µg
Day 1, Average flow rate, n=23, 2341.11 ± 11.29442.72 ± 11.593
Day 14, Average flow rate, n=23, 2342.29 ± 10.89541.36 ± 10.354
Day 1, PIFR, n=23, 2365.85 ± 16.64967.60 ± 16.097
Day 14, PIFR, n=23, 2367.36 ± 16.43264.79 ± 15.886
SecondaryInhalation Time on Days 1 and 14 of of the Respective Treatment Period

During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhalation time is defined as the duration of the inhalation(s) when inhaling across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalation time was determined.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · Seconds (sec)
Inhalation Time on Days 1 and 14 of of the Respective Treatment Period
Seconds (sec)FF 100 µg/VI 25 µgFF 100 µg
Day 1, n=23, 230.97 ± 0.3500.83 ± 0.385
Day 14, n=23, 230.96 ± 0.3140.91 ± 0.347
SecondaryInhaled Volume on Days 1 and 14 of the Respective Treatment Period

During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhaled volume is defined as the volume of air (Liters) inhaled during the inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalaled volume was determined.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · Liters
Inhaled Volume on Days 1 and 14 of the Respective Treatment Period
LitersFF 100 µg/VI 25 µgFF 100 µg
Day 1, n=23, 230.69 ± 0.3370.58 ± 0.285
Day 14, n=23, 230.68 ± 0.3080.65 ± 0.352
SecondaryPeak Pressure Drop on Days 1 and 14 of the Respective Treatment Period

During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Peak pressure drop is defined as the maximum pressure drop (kilopascal \[kPa\]) achieved during inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was calculated for each day (Days 1 and 14 of the respective treatment period), and used for subsequent modeling and prediction of dose emission attributes.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · Kilopascal (kpa)
Peak Pressure Drop on Days 1 and 14 of the Respective Treatment Period
Kilopascal (kpa)FF 100 µg/VI 25 µgFF 100 µg
Day 1, n=23, 233.79 ± 1.7063.97 ± 1.787
Day 14, n=23, 233.93 ± 1.8773.67 ± 1.611
SecondaryTotal Emitted Dose (TED) on Day 14 of the Respective Treatment Period

The total emitted dose (TED) is defined as the mass (micrograms) of the nominal dose that passes beyond the throat. The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted total emitted dose.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · micrograms
Total Emitted Dose (TED) on Day 14 of the Respective Treatment Period
microgramsFF 100 µg/VI 25 µgFF 100 µg
Nominal TED FF, n=23, 2387.58 ± 0.30586.33 ± 1.505
Minimum TED FF, n=23, 2387.64 ± 0.33086.72 ± 1.589
Maximum TED FF, n=23, 2387.51 ± 0.28985.93 ± 1.534
Nominal TED VI, n=23, 020.26 ± 0.162NA ± NA
Minimum TED VI, n=23, 020.22 ± 0.153NA ± NA
Maximum TED VI, n=23, 020.29 ± 0.175NA ± NA
SecondaryEx-throat Dose (ETD) and ETD <2 Microns on Day 14 of the Respective Treatment Period

The ex-throat dose (ETD) and the "nominal ETD" is the mass (micrograms) of active investigational material that passes beyond the throat, nominal being the mean. The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted ETD and ETD \<2 microns.

Time frame:
Day 14 of the respective treatment period (up to Study Day 63)
Reported as:
Mean · micrograms
Ex-throat Dose (ETD) and ETD <2 Microns on Day 14 of the Respective Treatment Period
microgramsFF 100 µg/VI 25 µgFF 100 µg
Nominal ETD FF, n=23, 2324.96 ± 5.80124.34 ± 8.574
Minimum ETD FF, n=23, 2323.38 ± 7.02322.99 ± 9.120
Maximum ETD FF, n=23, 2326.24 ± 4.82525.48 ± 8.197
ETD <2 microns FF, n=23, 236.66 ± 0.9485.97 ± 1.382
Minimum ETD <2 microns FF, n=23, 236.45 ± 0.7885.77 ± 1.319
Maximum ETD <2 microns FF, n=23, 236.92 ± 1.1476.21 ± 1.476
Nominal ETD VI, n=23, 08.54 ± 0.953NA ± NA
Minimum ETD VI, n=23, 08.33 ± 0.793NA ± NA
Maximum ETD VI, n=23, 08.80 ± 1.154NA ± NA
ETD <2 microns VI, n=23, 04.86 ± 1.162NA ± NA
Minimum ETD <2 microns VI, n=23, 04.60 ± 0.965NA ± NA
Maximum ETD <2 microns VI, n=23, 05.18 ± 1.409NA ± NA

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FF 100 µg/VI 25 µg—0/25 (0%)4/25 (16%)
FF 100 µg—0/25 (0%)1/25 (4%)
Most frequent other events
Most frequent other events
EventFF 100 µg/VI 25 µgFF 100 µg
BronchitisInfections and infestations1/250/25
Conjunctivitis viralInfections and infestations0/251/25
Pharyngitis streptococcalInfections and infestations1/250/25
Upper respiratory tract infectionInfections and infestations0/251/25
ConjunctivitisEye disorders1/250/25
HeadacheNervous system disorders1/250/25

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FF 100 µg/VI 25 µg and FF 100 µg in TPs 1 and 2
Mean8.1 ± 1.97
Gender
Gender(Participants)FF 100 µg/VI 25 µg and FF 100 µg in TPs 1 and 2
Female11
Male15
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FF 100 µg/VI 25 µg and FF 100 µg in TPs 1 and 2
African American/African Heritage3
White - Arabic/North African Heritage1
White - White/Caucasian/European Heritage21
African American/African Heritage & White1
08

Study locations

1 site
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2011
First posted
Oct 17, 2011
Start
Oct 2011
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Aug 9, 2013
Last update
Jan 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01453023
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 17, 2011
Start date
Oct 2011
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Aug 9, 2013
Last update
Jan 11, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Vilanterol

Start the discussion